top of page
  • Writer's pictureDT Economics

Cochlear-Oticon merger inquiry

Our managing partner, David Thomas, was today appointed to the Phase 2 inquiry group for this anticipated merger in the hearing implant sector.

The CMA has referred the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical, for an in-depth investigation. This assessment will identify whether this merger has resulted, or could result, in a substantial lessening of competition within a market or markets in the United Kingdom.





Further details on the CMA's case page:






Comments


bottom of page